Lyell Immunopharma, Inc. (LYEL) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 53 transactions totaling $673.0K, demonstrating a bearish sentiment with -$73.0K in net insider flow. The most recent transaction on Feb 10, 2026 involved a transaction of 50,000 shares valued at $0.
No significant insider buying has been recorded for LYEL in the recent period.
No significant insider selling has been recorded for LYEL in the recent period.
Based on recent SEC filings, insider sentiment for LYEL is bearish with an Insider Alignment Score of 45/100 and a net flow of -$73.0K. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Lyell Immunopharma, Inc. (LYEL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading LYEL stock, having executed 53 transactions in the past 90 days. The most active insider is Cathy Friedman (Executive), who has made 4 transactions totaling $300.0K.
Get notified when executives and directors at LYEL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | Shook David | Chief Medical Officer | Award | 50,000 | $N/A | $0 | |
| Feb 10, 2026 | Sanchez Bulis Veronica | VP, Corporate Controller | Sale | 254 | $23.12 | $5.9K | |
| Feb 10, 2026 | Sanchez Bulis Veronica | VP, Corporate Controller | Award | 8,750 | $N/A | $0 | |
| Feb 10, 2026 | A. Meltz Mark | General Counsel | Award | 50,000 | $N/A | $0 | |
| Feb 10, 2026 | Seely Lynn | Executive | Award | 155,000 | $N/A | $0 | |
| Feb 10, 2026 | Seely Lynn | Executive | Sale | 438 | $23.12 | $10.1K | |
| Feb 10, 2026 | K. Lee Gary | Chief Scientific Officer | Award | 50,000 | $N/A | $0 | |
| Feb 10, 2026 | K. Lee Gary | Chief Scientific Officer | Sale | 147 | $23.12 | $3.4K | |
| Feb 10, 2026 | J. Hill Stephen | Chief Operating Officer | Award | 65,000 | $N/A | $0 | C-Suite |
| Feb 10, 2026 | J. Hill Stephen | Chief Operating Officer | Sale | 109 | $23.12 | $2.5K | C-Suite |
| Feb 9, 2026 | Seely Lynn | Executive | Award | 20,000 | $N/A | $0 | |
| Feb 9, 2026 | K. Lee Gary | Chief Scientific Officer | Award | 4,000 | $N/A | $0 | |
| Feb 9, 2026 | J. Hill Stephen | Chief Operating Officer | Award | 4,000 | $N/A | $0 | C-Suite |
| Nov 10, 2025 | J. Hill Stephen | Executive | Sale | 95 | $16.12 | $1.5K | |
| Nov 10, 2025 | K. Lee Gary | Executive | Sale | 138 | $16.16 | $2.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 22 | $373.0K | 47.4% |
Purchase(P) | 1 | $300.0K | 38.1% |
Exercise(M) | 2 | $113.9K | 14.5% |
Award(A) | 18 | $0 | 0.0% |
Other(J) | 2 | $0 | 0.0% |
Conversion(C) | 8 | $0 | 0.0% |
Insider activity at Lyell Immunopharma, Inc. shows mixed signals across all time. While $300.0K in purchases indicates some executive confidence,$373.0K in sales balances the picture, resulting in a modest net flow of -$73.0K.14 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Cathy Friedman, has transacted $300.0K during this period.